| "Descrizione" by Al222 (24136 pt) | 2024-May-20 10:17 |
Tioconazolo è un composto chimico antifungino utilizzato per trattare le infezioni fungine della pelle e delle unghie.
Processo industriale di sintesi chimica
A cosa serve e dove si usa
Il Tioconazolo è un agente antifungino appartenente alla classe dei derivati azolici. È efficace nel combattere una vasta gamma di infezioni fungine, inclusi quelli che causano la tigna, il piede d'atleta e le infezioni delle unghie. Questo farmaco agisce inibendo la sintesi dell'ergosterolo, un componente vitale della membrana cellulare dei funghi, bloccando così la crescita e la riproduzione dei funghi. Viene comunemente utilizzato in creme, gel, e soluzioni topiche. Il Tioconazolo è apprezzato per la sua efficacia e la sua capacità di ridurre rapidamente i sintomi delle infezioni fungine (1).
Cosmetica - Funzioni INCI
Applicazioni commerciali
Trattamento antifungino. Il tioconazolo è usato in creme, gel e lozioni per trattare infezioni fungine come la tinea pedis (piede d'atleta), tinea cruris (tigna inguinale) e tinea corporis (tigna del corpo).
Prevenzione. Aiuta a prevenire la ricrescita dei funghi nelle aree trattate, mantenendo la pelle sana.
Versatilità. Può essere utilizzato in vari prodotti per la cura della pelle destinati al trattamento delle infezioni fungine localizzate (3).
![]() | ![]() |
Molecular Formula C16H13Cl3N2OS
Molecular Weight 387.7 g/mol
CAS 65899-73-2
UNII S57Y5X1117
EC Number 265-973-8
Synonyms:
Vagistat
Mykontral
Monistat
Trosderm
Trosid
Trosyd
Bibliografia_____________________________________________________________________
(1) Flores, F. C., Chiu, W. S., Beck, R. C., da Silva, C. B., & Delgado-Charro, M. B. (2018). Enhancement of tioconazole ungual delivery: Combining nanocapsule formulation and nail poration approaches. International Journal of Pharmaceutics, 535(1-2), 237-244.
(2) Clissold SP, Heel RC. Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs. 1986 Jan;31(1):29-51. doi: 10.2165/00003495-198631010-00003.
Abstract. Tioconazole is a substituted imidazole antimicrobial agent structurally related to other drugs in this group. It has been shown to have a broad spectrum of activity in vitro against dermatophytes and yeasts, as well as against some chlamydia, trichomonads and Gram-positive bacteria. Both open and controlled clinical trials have clearly demonstrated the efficacy and safety of topical preparations of tioconazole for treating superficial dermatophyte or yeast infections of the skin and vaginal candidiasis. In comparative studies it was at least as effective as alternative imidazole antifungal drugs, and in a few trials significantly greater efficacy has been reported for tioconazole, compared with clotrimazole, miconazole, econazole and systemic ketoconazole. Preliminary studies in other clinical areas suggest tioconazole may be useful for treating onychomycosis (in a special nail formulation), napkin-rash due to Candida albicans, impetigo, and vaginal trichomoniasis, although comparative studies are needed in each of these settings to clearly assess its relative place in therapy. Thus, tioconazole is an effective and well tolerated treatment for vaginal candidiasis and superficial fungal infections of the skin.
(3) Hay, R. J., Mackie, R. M., & Clayton, Y. M. (1985). Tioconazole nail solution—an open study of its efficacy in onychomycosis. Clinical and Experimental Dermatology, 10(2), 111-115.
Abstract. In view of the problems encountered in the treatment of onychomycosis with orally administered antifungal drugs, alternative forms of therapy arc needed. Tioconazole (28%) nail solution is a new topical preparation for use on infected nails. In this study 27 patients received treatment with tioconazole (28%) for up to 12 months. Six patients (22%) achieved complete clinical remission and were free of infection at follow-up, 3 months after therapy. They included infections caused by Trichophyton rubruni (4), Hendersonula toruloidea (1) and Acremonium (1). Apart from the latter, all infections responding to treatment were in the finger nails, even though three patients had active infection in the toe nails as well which did not respond to therapy. Significant improvements were recorded in a further 11 patients. They did not, however, achieve complete clinical and mycological recovery. The results indicate that cures of onychomycosis are possible after topical therapy, and further methods of using this form of treatment such as combined surgical and topical therapy are discussed.
| Evaluate |